XASXMAP
Market cap72mUSD
Jan 07, Last price
0.26AUD
1D
10.64%
1Q
48.57%
IPO
-30.67%
Name
Microba Life Sciences Ltd
Chart & Performance
P/E
—
P/S
9.63
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
7.11%
Rev. gr., 5y
45.91%
Revenues
12m
+123.06%
Net income
-20m
L+57.24%
CFO
-16m
L+25.60%
Profile
Microba Life Sciences Limited provides microbiome testing and analysis services for clinicians, consumers, and research customers in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. It offers pathology, therapeutics, and diagnostics services based on the human gut microbiome; Databank, for discovery of therapeutic leads, consumer health innovations, and diagnostic biomarkers; and data-driven therapeutics platform that develops novel monoclonal microbial cell therapies for inflammatory bowel disease, cancer immunotherapy, and autoimmune diseases. The company was incorporated in 2017 and is based in Brisbane, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | |
| Income | ||||||
Revenues | 12,090 123.06% | 5,420 15.60% | 4,689 25.62% | |||
Cost of revenue | 44,473 | 30,032 | 16,820 | |||
Unusual Expense (Income) | ||||||
NOPBT | (32,383) | (24,612) | (12,132) | |||
NOPBT Margin | ||||||
Operating Taxes | (51) | (6,089) | 9 | |||
Tax Rate | ||||||
NOPAT | (32,332) | (18,523) | (12,141) | |||
Net income | (19,938) 57.24% | (12,680) 10.55% | (11,470) 52.46% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 19,099 | 16,642 | 29,345 | |||
BB yield | -29.12% | -16.66% | -50.47% | |||
| Debt | ||||||
Debt current | 1,208 | 902 | 841 | |||
Long-term debt | 1,559 | 468 | 1,445 | |||
Deferred revenue | ||||||
Other long-term liabilities | 2,519 | 170 | 195 | |||
Net debt | (18,122) | (30,674) | (28,294) | |||
| Cash flow | ||||||
Cash from operating activities | (15,567) | (12,394) | (10,449) | |||
CAPEX | (1,487) | (3,037) | (1,873) | |||
Cash from investing activities | (13,949) | (2,999) | (1,732) | |||
Cash from financing activities | 18,394 | 16,684 | 29,216 | |||
FCF | (32,609) | (19,556) | (13,713) | |||
| Balance | ||||||
Cash | 20,889 | 32,044 | 30,581 | |||
Long term investments | ||||||
Excess cash | 20,285 | 31,773 | 30,346 | |||
Stockholders' equity | 41,216 | 38,574 | 33,536 | |||
Invested Capital | 25,032 | 6,954 | 4,710 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 409,859 | 332,990 | 290,710 | |||
Price | 0.16 -46.67% | 0.30 50.00% | 0.20 | |||
Market cap | 65,577 -34.35% | 99,897 71.82% | 58,142 | |||
EV | 47,455 | 69,223 | 29,848 | |||
EBITDA | (32,383) | (22,970) | (10,589) | |||
EV/EBITDA | ||||||
Interest | 69 | 60 | 8 | |||
Interest/NOPBT | ||||||